Six years after regulators approved Amjevita, a biosimilar to the nation’s most lucrative drug, Humira, Amgen’s drug jumped on the U.S. market Jan. 31 with two list prices.
Read the full post on Becker's Hospital Review - Healthcare News
1st Humira biosimilar enters market with two prices
